Zacks Investment Research Upgrades Theseus Pharmaceuticals (NASDAQ:THRX) to “Hold”

Theseus Pharmaceuticals (NASDAQ:THRX – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports.

According to Zacks, “Theseus Pharmaceuticals Inc. is a biopharmaceutical company. It focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company’s principal product candidate includes THE-630. Theseus Pharmaceuticals Inc. is based in CAMBRIDGE, Mass. “

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Theseus Pharmaceuticals in a research note on Friday, April 1st. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $22.40.

NASDAQ:THRX opened at $7.35 on Thursday. The company has a 50 day moving average price of $10.87 and a 200-day moving average price of $11.85. Theseus Pharmaceuticals has a 1-year low of $7.00 and a 1-year high of $24.54.

Theseus Pharmaceuticals (NASDAQ:THRX – Get Rating) last released its quarterly earnings results on Thursday, March 10th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). Analysts expect that Theseus Pharmaceuticals will post -1.26 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Strs Ohio acquired a new stake in Theseus Pharmaceuticals during the 4th quarter worth $34,000. Citigroup Inc. acquired a new stake in Theseus Pharmaceuticals during the 4th quarter worth $40,000. JPMorgan Chase & Co. acquired a new stake in Theseus Pharmaceuticals during the 4th quarter worth $65,000. California State Teachers Retirement System acquired a new stake in Theseus Pharmaceuticals during the 4th quarter worth $80,000. Finally, Wells Fargo & Company MN acquired a new stake in Theseus Pharmaceuticals during the 4th quarter worth $86,000. 90.00% of the stock is currently owned by institutional investors.

About Theseus Pharmaceuticals (Get Rating)

Theseus Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial.

Featured Articles